Latest available resultsQuarter ended June 30, 202610-Q · August 5, 2026
Filed with the SECZIMMER BIOMET HOLDINGS, INC.
ZBHHealthcare
Next reportNovember 3, 2026pre-market · Analyst forecast 1.901 $/share
Revenue
$2.18B
▲ +4.8% vs prior year% YoY
Net income
$198.30M
▲ +29.8% vs prior year% YoY
EPS
1.03$
▲ +33.8% vs prior year% YoY
Net margin
9.1%
▲ +1.8 percentage points vs prior year pp YoY
Revenue▲ +4.8 %
Margins (% of revenue)GrossOperatingNet
Net income▲ +29.8 %
EPS▲ +33.8 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $2.18B | |
| Gross profit | $1.54B | 70.8 % |
| Operating income | $326.10M | 15.0 % |
| Net income | $198.30M | 9.1 % |
| R&D | — | |
| EPS (diluted) | 1.03 $ | |
| Balance sheet | ||
| Assets | $22.80B | |
| Liabilities | $10.17B | |
| Equity | $12.63B | |
| Cash | $410.00M | |
| Capital | ||
| Shares outstanding | 190.74M | as of 2026-07-30 |
| Public float | — | |